Search Within

Gynecologic Medicine Service

Formats
  1. Journal Article (1104)
  2. Meeting Abstract (902)
  3. Review (55)
  4. Book Section (46)
  5. Editorial (36)
  6. Guidelines (22)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Solid Tumor Oncology Division (2180)
  2. Department of Medicine (2174)
  3. Gynecology Disease Management Team (1877)
  4. GDMT, Medicine (1859)
  5. Surgery (603)
  6. GDMT, Surgery (479)

More Groups

People
  1. Carol Aghajanian (615)
  2. Nadeem Abu-Rustum (292)
  3. Martee Hensley (290)
  4. Roisin O'Cearbhaill (273)
  5. Vicky Makker (269)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (75)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (458)
  2. Gynecologic Oncology (420)
  3. International Journal of Gynecological Cancer (161)
  4. Annals of Oncology (117)
  5. Clinical Cancer Research (71)
  6. Cancer Research (55)

More Publications

Publishers
  1. American Society of Clinical Oncology (498)
  2. Elsevier B.V. (446)
  3. Lippincott Williams & Wilkins (188)
  4. American Association for Cancer Research (173)
  5. Oxford University Press (144)
  6. Elsevier Inc. (128)

More Publishers

Results (2180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecologic cancers in the Foundation Medicine genomic database
    Meeting Abstract

    Dockery, L.; Richardson, D.; Neff, R.; Green, A.; Priebe, A.; Iyer, G.; Palma, N.; Navarro, W.; Moore, K.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Folate receptor positivity in low-grade serous ovarian cancer: Exploring new therapeutic possibilities
    Meeting Abstract

    Manning-Geist, B.; Sullivan, M.; Zhou, Q.; Iasonos, A.; Stallworth, C.; Liu, Y.; Roche, K. L.; Gordhandas, S.; Chi, D.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Sensitivity of HER2-low uterine carcinosarcoma organoids to the antibody-drug conjugate, trastuzumab deruxtecan
    Meeting Abstract

    Moufarrij, S.; Dopeso, H.; Green, H.; Gill, K.; Brown, D.; Zammarrelli, W.; Varice, N.; Wu, M.; Paula, A. D.; de Oliveira, T. B.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Molecular and tumor microenvironmental characterization of HPV-negative invasive squamous cell carcinoma of the vulva
    Meeting Abstract

    Moufarrij, S.; Filippova, O.; Paula, A. D.; Heredia, J. B.; Leitao, M.; O'Cearbhaill, R.; Abu-Rustum, N.; Park, K.; Weigelt, B.; Zamarin, D.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Concurrent POLE hotspot mutations and mismatch repair deficiency in endometrial cancer: Defining cancer drivers
    Meeting Abstract

    Moufarrij, S.; Gazzo, A.; Selenica, P.; Abu-Rustum, N.; Ellenson, L.; Liu, Y.; Weigelt, B.; Momeni-Boroujeni, A.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study
    Meeting Abstract

    Marth, C.; Moore, R.; Bidzinski, M.; Pignata, S.; Ayhan, A.; Rubio, M. J.; Beiner, M.; Hall, M.; Vulsteke, C.; Braicu, E. I.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial
    Meeting Abstract

    Harter, P.; Wimberger, P.; Okamoto, A.; Reuss, A.; Lim, M. C.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Trédan, O.; Hietanen, S.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer
    Meeting Abstract

    Colombo, N.; Van Gorp, T.; Matulonis, U.; Oaknin, A.; Grisham, R.; Provencher, D.; Fleming, G.; Olawaiye, A.; Pashova, H.; Tudor, I. C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation
    Meeting Abstract

    Schram, A.; Shapiro, G.; Thompson, J.; Vandross, A.; Kummar, S.; El-Khoueiry, A.; LeDuke, K.; Fellous, M.; Alland, L.; Dumbrava, E.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Mainstreaming in gynecologic oncology clinics triples the odds of genetic testing among patients with epithelial ovarian cancer
    Meeting Abstract

    Sia, T.; Byrne, M.; Fong, C.; Khurram, A.; Zhou, Q.; Saban, S.; Wu, M.; Varice, N.; Hamilton, J.; Carrot Zhang, J.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save